公开(公告)号：US20210388453A1

公开(公告)日：2021-12-16

申请号：US17411606

申请日：2021-08-25

Applicant: Exosome Diagnostics, Inc.

Inventor： Mikkel NOERHOLM ,  Susan BELZER ,  Charlotte ROMAIN ,  Johan Karl Olov SKOG ,  Leileata M. RUSSO ,  Wayne COMPER

IPC: C12Q1/6886 ,  C12N7/00

Abstract: The present invention features a method and kit for isolating microvesicles or extracting microvesicle nucleic acids from a biological sample by using a control particle. The present invention provides control particles that are viruses or virus-like particles, such as bacteriophages, that contain control nucleic acids that can be detected to assess the accuracy, reliability, and efficiency of the microvesicle isolation or nucleic acid extraction steps. The methods described herein may further comprise the analysis of the presence, absence, or level of at least one biomarker associated with a disease or medical condition for diagnosing, prognosing, or monitoring the disease or medical condition.

公开(公告)号：US20220333203A1

公开(公告)日：2022-10-20

申请号：US17532363

申请日：2021-11-22

Applicant: Exosome Diagnostics, Inc.

Inventor： Leileata M. RUSSO

IPC: C12Q1/6886

Abstract: A method for detecting biomarkers of prostate cancer or other medical condition of the prostate based on the use of microvesicles obtained from urine samples, and the nucleic acids present in the microvesicles. The method disclosed herein are advantageous in that they may be used to support diagnosis, prognosis, monitoring, or therapy selection in lieu of or in conjunction with traditional biopsy-based diagnostics and do not require a digital rectal examination or prostate massage prior to urine sample collection.

公开(公告)号：US20210207124A1

公开(公告)日：2021-07-08

申请号：US17211484

申请日：2021-03-24

Applicant: Exosome Diagnostics, Inc.

Inventor： Johan Karl Olov SKOG ,  Leileata M. RUSSO

IPC: C12N15/10

Abstract: A method for extracting nucleic acids from a biological sample by isolating nucleic acid-containing particles from the biological sample by one or more centrifugation procedures, performing one or more steps to mitigate adverse factors that prevent or might prevent high quality nucleic acid extraction, and extracting nucleic acids from the isolated particles. The centrifugation procedures are performed at a speed not exceeding about 200,000 g. The extracted nucleic acids contain both 18S and 28S rRNA.